SAN DIEGO, May 17, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings in-person at the H.C. Wainwright Global Investment Conference, which is taking place in Miami, Florida from May 23 – 26, 2022.
Details on the fireside chat can be found below.
H.C. Wainwright Global Investment Conference | |
Date: | May 24, 2022 |
Time: | 5:00 PM ET |
Webcast Link: | https://journey.ct.events/view/584e1f6d-5db2-432b-888c-7a27b587ea43 |
A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.
About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact: Vicki Kelemen Chief Operating Officer 858-952-7652 vkelemen@cardiffoncology.com
Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com
Media Contact: Amy Jobe, Ph.D. LifeSci Communications 315-879-8192 ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-hc-wainwright-global-investment-conference-301548838.html
SOURCE Cardiff Oncology, Inc.